Polygenic Risk Scores for Glaucoma Onset in the Ocular Hypertension Treatment Study

Author:

Singh Rishabh K.12,Zhao Yan3,Elze Tobias2,Fingert John4,Gordon Mae5,Kass Michael A.5,Luo Yuyang3,Pasquale Louis R.6,Scheetz Todd4,Segrè Ayellet V.37,Wiggs Janey L.37,Zebardast Nazlee3

Affiliation:

1. Department of Ophthalmology, Columbia University Medical Center, New York, New York

2. Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts

3. Massachusetts Eye and Ear, Harvard Medical School, Boston

4. Carver College of Medicine, University of Iowa, Iowa City

5. Washington University School of Medicine, St Louis, Missouri

6. Icahn School of Medicine at Mount Sinai, New York, New York

7. Ocular Genomics Institute, Massachusetts Eye and Ear, Boston

Abstract

ImportancePrimary open-angle glaucoma (POAG) is a highly heritable disease, with 127 identified risk loci to date. Polygenic risk score (PRS) may provide a clinically useful measure of aggregate genetic burden and improve patient risk stratification.ObjectiveTo assess whether a PRS improves prediction of POAG onset in patients with ocular hypertension.Design, Setting, and ParticipantsThis was a post hoc analysis of the Ocular Hypertension Treatment Study. Data were collected from 22 US sites with a mean (SD) follow-up of 14.0 (6.9) years. A total of 1636 participants were followed up from February 1994 to December 2008; 1077 participants were enrolled in an ancillary genetics study, of which 1009 met criteria for this analysis. PRS was calculated using summary statistics from the largest cross-ancestry POAG meta-analysis, with weights trained using 8 813 496 variants from 449 186 cross-ancestry participants in the UK Biobank. Data were analyzed from July 2022 to December 2023.ExposuresFrom February 1994 to June 2002, participants were randomized to either topical intraocular pressure–lowering medication or close observation. After June 2002, both groups received medication.Main Outcomes and MeasuresOutcome measures were hazard ratios for POAG onset. Concordance index and time-dependent areas under the receiver operating characteristic curve were used to compare the predictive performance of multivariable Cox proportional hazards models.ResultsOf 1009 included participants, 562 (55.7%) were female, and the mean (SD) age was 55.9 (9.3) years. The mean (SD) PRS was significantly higher for 350 POAG converters (0.24 [0.95]) compared with 659 nonconverters (−0.12 [1.00]) (P < .001). POAG risk increased 1.36% (95% CI, 1.08-1.64) with each higher PRS decile, with conversion ranging from 9.52% (95% CI, 7.09-11.95) in the lowest PRS decile to 21.81% (95% CI, 19.37-24.25) in the highest decile. Comparison of low-risk and high-risk PRS tertiles showed a 2.0-fold increase in 20-year POAG risk for participants of European and African ancestries. In the subgroup randomized to delayed treatment, each increase in PRS decile was associated with a 0.52-year (95% CI, 0.01-1.03) decrease in age at diagnosis (P = .047). No significant linear association between PRS and age at POAG diagnosis was present in the early treatment group. Prediction models significantly improved with the addition of PRS as a covariate (C index = 0.77) compared with the Ocular Hypertension Treatment Study baseline model (C index = 0.75) (P < .001). Each 1-SD higher PRS conferred a mean hazard ratio of 1.25 (95% CI, 1.13-1.44) for POAG onset.Conclusions and RelevanceHigher PRS was associated with increased risk for POAG in patients with ocular hypertension. The inclusion of a PRS improved the prediction of POAG onset.Trial RegistrationClinicalTrials.gov Identifier: NCT00000125

Publisher

American Medical Association (AMA)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3